Autoimmunity is controlled in healthy individuals by cells that actively control immune responses to self so that the body is tolerant of it’s own tissues. The Long Lab focuses on understanding mechanisms of tolerance, why they are lost in autoimmunity, and how tolerance can be augmented with therapy.
Our approach combines in-depth characterization of T cells that confer tolerance, discovery of drivers of tolerance, and testing of how therapies modulate tolerance in trials. We use cutting-edge single cell assays to assess rare antigen-specific responses in clinical samples, with a focus on type 1 diabetes and related autoimmune diseases. These approaches are complemented by work in the Human Immunophenotyping Core.
Our goal is to better treat and prevent autoimmunity by augmenting T cell tolerance.
S. Alice Long, PhD
Past Lab Members
- Valerie Wall – Notch Therapeutics
- Rebecca LaFond – Mason Univeristy
- Duangchan Suwannasaen – Flow Contract Site
- Katharine Schwedhelm – Fred Hutch
- Lori Blanchfeild – Alpine Immune Sciences
- Bryce Fuchs – University of Utah
- Jerill Thorpe – Bristol Myers Squibb
- Megan Maers – University of Washington
- Nathan Alidina – AGC Biologics
- Ian Frank – Sony Biotechnology
Mechanisms of tolerance with autoimmune therapies
Impact of IL-2/IL-2R signaling in T1D
Drivers of CD8 T cells exhaustion in autoimmunity
Meet BRI's Summer 2023 Interns
Prediction and Prevention: A New Paradigm in Autoimmune Disease
Immunology to Change Lives: Where We're Going in 2023
BRI was formed with a clear plan: First, answer key fundamental questions about the immune system. Then, build on those answers to change lives. This is a very exciting time because we’re reaching that second stage of the plan.